Trastuzumab deruxtecan
Pre-clinicalRecruiting 0 watching 0 views this week๐ค Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Unresectable Breast Cancer
Conditions
Unresectable Breast Cancer, Metastatic Breast Cancer, HER2-low Expressing Breast Cancer
Trial Timeline
Oct 24, 2023 โ Sep 1, 2028
NCT ID
NCT05945732About Trastuzumab deruxtecan
Trastuzumab deruxtecan is a pre-clinical stage product being developed by Daiichi Sankyo for Unresectable Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05945732. Target conditions include Unresectable Breast Cancer, Metastatic Breast Cancer, HER2-low Expressing Breast Cancer.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (19)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07015697 | Phase 1 | Recruiting |
| NCT06750484 | Phase 2 | Recruiting |
| NCT05982678 | Phase 2 | Recruiting |
| NCT06386263 | Pre-clinical | Completed |
| NCT06210776 | Pre-clinical | Recruiting |
| NCT05950945 | Phase 3 | Recruiting |
| NCT05993234 | Pre-clinical | Recruiting |
| NCT05945732 | Pre-clinical | Recruiting |
| NCT05458401 | Pre-clinical | Completed |
| NCT05246514 | Phase 2 | Active |
| NCT04989816 | Phase 2 | Completed |
| NCT04739761 | Phase 3 | Active |
| NCT04644237 | Phase 2 | Completed |
| NCT04639219 | Phase 2 | Active |
| NCT04482309 | Phase 2 | Recruiting |
| NCT04752059 | Phase 2 | Completed |
| NCT04420598 | Phase 2 | Completed |
| NCT04014075 | Phase 2 | Completed |
| NCT03505710 | Phase 2 | Terminated |
Competing Products
20 competing products in Unresectable Breast Cancer